Amarin to Participate in the Leerink Partners 6th Annual Global Healthcare Conference

BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 09, 2017 -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the company will participate in the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, Feb. 16^th, at Lotte New York Palace, New York, NY.  John F. Thero, Amarin's president and chief executive officer, will represent the company in a question-and-answer session with the host analyst beginning at 2:30 p.m. (Eastern Time).

A live audio webcast of the presentation will be available at http://investor.amarincorp.com/events.cfm. An audio replay will also be available at the same link for at least two days following the conference.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit www.vascepa.com. For more information about Amarin, visit www.amarincorp.com.

Availability of Other Information about Amarin

Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://investor.amarincorp.com/index.cfm), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin contact information

Investor Relations: 
Gene Mack 
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
[email protected]

Lee M. Stern
Trout Group 
In U.S.: +1 (646) 378-2922
[email protected]

Media Inquiries: 
Kristie Kuhl
Finn Partners
In U.S.: +1 (212) 583-2791
[email protected]